Novel, Immunogenicity Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development 07.08.2025 - 18:04:12 EpiVax, Inc. Japan South Korea Taiwan Rhode Island View original content:https://www.prnewswire.co.uk/news-releases/novel-immunogenicity-risk-assessment-platform-ispri-facilitates-biologic-therapeutics-development-302103725.html
